NASDAQ:REVB

Revelation Biosciences Q3 2025 Earnings Results & Report

Revelation Biosciences logo
$3.97 +0.09 (+2.27%)
Closing price 03:58 PM Eastern
Extended Trading
$3.93 -0.04 (-1.03%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revelation Biosciences missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$49.56 versus the -$37.52 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Revelation Biosciences EPS Results

Actual EPS
-$49.56
Consensus EPS
-$37.52
Beat/Miss
Missed by -$12.04
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 5 quarters

Revelation Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Revelation Biosciences Q3 2025 Earnings FAQ

Revelation Biosciences (NASDAQ:REVB) reported earnings of -$49.56 per share for Q3 2025, missing the consensus estimate of -$37.52. The report was announced on Thursday, November 6, 2025.

Revelation Biosciences Earnings Headlines

Research Analysts Offer Predictions for REVB FY2026 Earnings
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Analysts Set Expectations for REVB Q1 Earnings
See More Revelation Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email.

About Revelation Biosciences

Revelation Biosciences (NASDAQ:REVB) is a clinical-stage biotechnology company developing treatments that target the innate immune system. Its research focuses on potential therapies for infectious and other diseases.

The company’s lead program, Gemini, is an intranasal formulation of an immune-stimulating compound designed to activate Toll-like receptor 4. Revelation has investigated Gemini as a potential way to help prevent or treat respiratory infections.

Revelation’s work is centered on developing its therapeutic candidates; the company has not established a broad commercial product portfolio. Its programs remain in development.

View Revelation Biosciences Profile